Business Desk :
Novo Nordisk, a global healthcare company, ranks second on the 2014 Access to Medicine Index, climbing four places since the 2012 Index, says a press release.
The company provided medical treatments for approximately 24.3 million people with diabetes worldwide, showing a 7percent in 2013 increase compared with 2012.
“Now, more than 80percent of people with diabetes live in low- and middle-income countries where access to medicine and treatment is simply not adequate for the millions in need,” says Lars Rebien Sørensen, chief executive officer of Novo Nordisk.
“Last year, we launched our Strategy for Global Access to Diabetes Care strengthening our already existing efforts to break down barriers that inhibit access to care and help us reach 40 million people living with diabetes by 2020.”
Since Novo Nordisk launched its first access to care strategy in 2001, diabetes has become a major global health challenge.
Novo Nordisk, a global healthcare company, ranks second on the 2014 Access to Medicine Index, climbing four places since the 2012 Index, says a press release.
The company provided medical treatments for approximately 24.3 million people with diabetes worldwide, showing a 7percent in 2013 increase compared with 2012.
“Now, more than 80percent of people with diabetes live in low- and middle-income countries where access to medicine and treatment is simply not adequate for the millions in need,” says Lars Rebien Sørensen, chief executive officer of Novo Nordisk.
“Last year, we launched our Strategy for Global Access to Diabetes Care strengthening our already existing efforts to break down barriers that inhibit access to care and help us reach 40 million people living with diabetes by 2020.”
Since Novo Nordisk launched its first access to care strategy in 2001, diabetes has become a major global health challenge.
